Vaccines against meningococcal disease: current and future technologies

Area of Science:

• Microbiology and Immunology
• Vaccine Development
• Infectious Disease Prevention

Background:

• Meningococcal serogroup C conjugate vaccines represent a significant advancement in preventing meningococcal disease.
• Challenges remain in developing vaccines for meningococcal serogroup B.

Purpose of the Study:

• To review recent developments in meningococcal vaccines.
• To examine future vaccine candidates for meningococcal disease.

Main Methods:

• Analysis of historical polysaccharide vaccines.
• Evaluation of conjugate vaccine technology.
• Exploration of outer membrane proteins (OMPs) and lipopolysaccharides (LPS) for serogroup B vaccines.
• Consideration of genome sequencing technologies.

Main Results:

• Polysaccharide vaccines targeted bacterial capsule components.
• Conjugate vaccines improved immunogenicity by linking polysaccharides to proteins.
• OMPs and LPS are key targets for serogroup B vaccine development.
• Genome sequencing offers a path toward broadly cross-protective vaccines.

Conclusions:

• Advances in vaccine technology have significantly impacted meningococcal disease prevention.
• Future meningococcal vaccines, particularly for serogroup B, will likely leverage novel targets and technologies like genome sequencing.